The Efficacy of Transcutaneous Auricular Vagus Nerve Stimulation in Individuals With Tiletamine Use Disorder

Participants diagnosed with tiletamine use disorder will be assigned to active or sham taVNS for 5 days. Clinical outcomes ( e.g., behavioral paradigms measures and clinical scales ) and physiological markers (e.g., EEG and ECG) will be evaluated at baseline, post-treatment, and 3-month follow-ups to determine therapeutic efficacy and mechanisms of action.

NCT Number	NCT07689981
Lead Sponsor	Shanghai Mental Health Center
Conditions	Tiletamine Use Disorder, Substance Use Disorder (SUD), Drug Craving
Enrollment	30 participants
Start Date	2026-07-01
Primary Completion	2027-12-01 (estimated)
Study Completion	2028-01-01 (estimated)
Updated on ClinicalTrials.gov	2026-07-08